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Abstract
Objectives To determine the repeatability and response to
therapy of dynamic contrast-enhanced (DCE) MRI bio-
markers of synovitis in the hand and wrist of rheumatoid ar-
thritis (RA) patients, and in particular the performance of the
transfer constant Ktrans, in a multicentre trial setting.
Methods DCE-MRI and RA MRI scoring (RAMRIS) were
performed with meticulous standardisation at baseline and 6
and 24 weeks in a substudy of fostamatinib monotherapy in
reducing synovitis compared with placebo or adalimumab.
Analysis employed statistical shape modelling to avoid biased
regions-of-interest, kinetic modelling and heuristic analyses.
Repeatability was also evaluated.
Results At early study termination, DCE-MRI data had been ac-
quired from 58 patients in 19 imaging centres. Ktrans intra-subject
coefficient of variation (N=14) was 30%. Ktrans change demon-
strated inferiority of fostamatinib (N=11) relative to adalimumab
(N= 10) after 6 weeks (treatment ratio = 1.92, p = 0.003), and
failed to distinguish fostamatinib from placebo (N=10, p = 0.79).
RAMRIS showed superiority of fostamatinib relative to placebo at
6 weeks (p = 0.023), and did not distinguish fostamatinib from
adalimumab at either 6 (p = 0.175) or 24 (p = 0.230) weeks.
Conclusion This demonstrated repeatability of Ktrans and its
ability to distinguish treatment groups show that DCE-MRI bio-
markers are suitable for use in multicentre RA trials.
Key Points
• DCE-MRI biomarkers are feasible in large multicentre stud-
ies of joint inflammation.
• DCE-MRI Ktrans showed fostamatinib inferior to
adalimumab after 6 weeks.
•Ktrans repeatability coefficient of variation was 30%
multicentre.
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CoV Coefficient of variation
DAS-28 CRP Disease Activity Score calculated from 28
joints and using C-reactive protein
DCE-MRI Dynamic contrast-enhanced MRI
DMARD Disease-modifying anti-rheumatic drug
Gd-CA Gadolinium-based contrast agent
IAUC60 IAUC120/
mM.s
Initial area under the Gd-CA concentration
curve over 60 s or 120 s post-arrival in
tissue
IRE/ mM.s-1 Initial rate (gradient) of enhancement fol-
lowing Gd-CA over 60 s post-arrival in
tissue
Ktrans/min-1 Volume transfer constant for Gd-CA be-
tween blood plasma and extravascular ex-
tracellular space
MCP Metacarpophalangeal
ME/mM Maximum enhancement of Gd-CA con-
centration curve during DCE-MRI series
MRI Magnetic resonance imaging
OMERACT Outcome measures in rheumatology
initiative
OSKIRA Oral SYK inhibition in RA
QC Quality control
RA Rheumatoid arthritis
RAMRIS RA MRI score
ROI Region of interest
SD Standard deviation
SPGR Spoiled gradient-recalled echo
SYK Spleen tyrosine kinase
T1 /s Longitudinal relaxation time
td Treatment difference
tr Treatment ratio
ve Volume of extravascular extracellular space
per unit volume tissue
vp Volume of blood plasma volume per unit
volume tissue
VEP/ml Volume of enhancing pannus
Introduction
MRIwith gadolinium-based contrast agents (Gd-CAs) provides
biomarkers dependent on perfusion, vascular volume, capillary
endothelial permeability and interstitial volume, all of which
increase in inflammation. MRI is widely available, sensitive, a
low risk to patients and amenable to quantitation. OMERACT
(OutcomeMeasures in Rheumatology) RAMRIS (Rheumatoid
Arthritis MRI scoring) [1, 2] synovitis score is well established
[3], but, as an ordinal variable, is theoretically less sensitive than
a continuous variable [4] as a biomarker. Also, RAMRIS re-
ports amount (an ‘extensive’ variable), but not severity (an
‘intensive’ variable), of synovitis, and cannot distinguish the
importance of extent versus intensity of inflammation in RA,
which is currently unknown.
Dynamic contrast enhanced (DCE) MRI [5] characterises
regional uptake and washout of Gd-CA. It has been extensive-
ly used in oncology [6] and other diseases, and in RA provides
biomarkers of synovial inflammation [7]. Despite over 60
DCE-MRI RA studies (over 1,000 patients) in PubMed,
DCE-MRI RA studies until recently [8] were performed only
in single expert centres, or occasionally [9] in two centres with
identical equipment. RAMRIS, however, is routinely
employed in large multicentre studies using different vendors’
MRI equipment [3]. A likely reason for failure to exploit
DCE-MRI in multicentre RA studies is that the heuristic var-
iables commonly used to characterise synovial Gd-CA uptake
curves are inherently scanner-dependent, and therefore unlike-
ly to provide biomarker values comparable between centres
and studies. Also, as with any intensive variable, DCE-MRI
biomarkers depend on how their region-of-interest (ROI) is
defined, and because of variations in patient positioning and
other technical factors, it is difficult to ensure that ROIs cor-
respond between time points and subjects.
We reasoned that with rigorous site qualification and scan-
ner monitoring, objective definition of ROIs by statistical
shape modelling and robustly quantified compartmental
modelling, we could reliably measure DCE-MRI biomarkers
even in a largemulticentre study using a variety ofMRI equip-
ment in centres with little or no previous quantitative DCE-
MRI experience.
Here we present multicentre DCE-MRI, repeatability and
response to treatment, in a study [10] of fostamatinib [11].
Methods (see Supplementary Material for detail)
Patients and treatment
The MRI substudy to OSKIRA-4 (Oral SYK Inhibition in
Rheumatoid Arthritis) [10] (ClinicalTrials.gov Identifier:
NCT02092961) was a Phase IIB, multicentre, randomised, dou-
ble-blind, placebo-controlled, parallel-group study of efficacy
and safety of fostamatinib disodium (a spleen tyrosine kinase
inhibitor) monotherapy, compared with placebo or adalimumab
monotherapy in patients with active RA. The primary substudy
objective was to assess the efficacy of fostamatinib in reducing
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joint synovial disease activity as measured by change from base-
line to week 6 (vs. placebo) in OMERACT RAMRIS synovitis
score. Exploratory objectives included assessment of efficacy of
fostamatinib in reducing joint synovial disease activity as mea-
sured by change from baseline to week 6 (vs. placebo and
adalimumab) and week 24 (vs. adalimumab) in certain DCE-
MRI biomarkers including Ktrans.
The findings of the full OSKIRA-4 clinical trial are report-
ed elsewhere [10]. All patients gave written informed consent.
Patients were DMARD-naïve, intolerant to DMARDs or had
had inadequate response to maximally two DMARDs.
Patients were randomised to one of three treatments:
fostamatinib (100 mg bid for 24 weeks plus placebo subcuta-
neous injection every 2 weeks); adalimumab (40 mg subcuta-
neous injection every 2 weeks for 24 weeks, plus placebo to
fostamatinib bid); placebo bid for 6 weeks followed by switch
to 100 mg fostamatinib bid up to week 24, plus placebo sub-
cutaneous injection every 2 weeks.
The more clinically active hand and wrist was imaged at
screening, week 6 and week 24 using 3.0 T or 1.5 T whole-
body MRI, with knee coils to allow simultaneous scanning of
MCP and wrist joints. An acrylic frame ensured reproducible
hand/wrist positioning. Some patients provided an additional
baseline scan before the first dose of randomised treatment. All
randomised patients were to have contrast-enhanced MRI (CE-
MRI) assessments at the scheduled time points. Where partici-
pating sites could demonstrate acceptable DCE-MRI perfor-
mance, this more technically demanding acquisition (subject of
this report) was also performed. Approximately 20 patients in
each dosing regimen were planned to have DCE-MRI evaluable
at baseline, week 6 and week 24. On 4 June 2013, AstraZeneca
announced results from Phase III trials of fostamatinib, and its
decision not to proceed with regulatory filings, following which
this study was terminated early.
DCE-MRI biomarkers
Pre-specified DCE-MRI biomarkers (Fig. 1c–g), in priority
order, were:
Ktrans/min-1: volume transfer constant for Gd-CA be-
tween blood plasma and extravascular extracellular space
from extended Tofts [5] compartmental model.
Fig. 1 Post-contrast high resolution T1-weighted spoiled gradient-
recalled echo (SPGR) image with fat saturation shows predominant dis-
ease in the secondmetacarpal joint (MCP) and isolated areas of disease in
MCP-5, the distal radio-ulnar and radio-carpal joints (a). Segmented joint
voxel masks were produced for each joint and used in the DCE-MRI
analysis (b). Pre-contrast images with DCE-MRI parameterisation over-
lays for: Ktrans (c), vp (d), IAUC120 (e), IRE (f) andME (g)
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IRE/ mM.s-1: initial rate (gradient) of enhancement fol-
lowing Gd-CA over 60 s post-arrival in tissue.
IAUC60, IAUC120/mM.s: initial area under Gd-CA con-
centration curve over 60 s or 120 s post-arrival in tissue.
VEP/mL: volume of enhancing pannus [12].
ME/mM: maximum enhancement of Gd-CA concentra-
tion curve during DCE-MRI series.
ve, vp: volumes respectively of extravascular extracellular
space, and blood plasma volume, per unit volume tissue
(dimensionless).
Each biomarker was measured voxelwise over a ROI de-
fined objectively using statistical shape modelling.
Statistical analysis
Analyses followed a predetermined statistical analysis plan,
finalised and signed prior to locking the database and
unblinding. Fostamatinib was compared pairwise with place-
bo (week 6) and adalimumab (weeks 6 and 24). Endpoints
were tested at a two-sided significance level of 10%. Double
baseline DCE-MRI repeatability was assessed using a mixed
model of the two baseline results only.
Results
No new safety findings inconsistent with the known profiles
of adalimumab, fostamatinib or any of the contrast agents
were reported in the substudy. Prone MRI, with arm over
head, may be uncomfortable for patients, but most tolerated
the procedure well, providing images without unacceptable
motion artefact (Fig. 1). Although the DCE-MRI protocol is
not longer than the CE-MRI protocol, for DCE-MRI patients
must remain immobile for the entire 26- to 28-min scan. We
did not prospectively seek to evaluate relative tolerability of
DCE-MRI and CE-MRI; informal records, however, indicate
that of 64 who had both, two were unable to remain still
during the dynamic scans because of discomfort, resulting in
excessive motion artefact, and transferred to the CE-MRI-only
cohort after baseline. In addition, four whose DCE-MRI failed
quality control at baseline declined repeat scans because of
discomfort and unwillingness to repeat MRI so quickly. No
other patient withdrew for reasons connected with MRI.
Fourteen patients from six centres provided two valid DCE-
MRI datasets and RAMRIS scores at baseline allowing repeat-
ability to be determined (Table 1). Demography was generally
balanced across treatment arms (Table S1). Because of early
study termination, fewer data were accrued than planned: 58
Table 1 Repeatability and range, averaging over diseased and non-diseased joints
MR biomarker Patients with two baseline scans Treated patients at baseline




N for range Geometric
mean
Range
Ktrans (min-1) 14 30.0% 59.3% 45 0.069 0.025–0.273
IRE (mM.s-1) 14 29.5% 51.3% 45 0.003 0.001–0.013
IAUC60 (mM.s) 14 31.4% 58.3% 45 7.69 1.92–28.17
IAUC120 (mM.s) 14 29.3% 55.7% 45 18.23 5.58–70.27
VEP (mL) 15 22.0% 41.3% 45 1.06 0.20–2.48*
ME (mM) 14 27.5% 52.4% 45 0.32 0.11–1.31
ve (%) 0 n/a n/a 0 n/a n/a
vp (%) 14 53.4% 60.1% 45 1.2 0.3–4.5
RAMRIS synovitis score** 13 1.30 (SD) 6.20 (SD) 31 6.95
(arithmetic mean)
0.0–21.8
*VEP excludes non-enhancing pannus. The range for total (non-enhancing plus enhancing) pannus was 3.29-8.30 ml
** VEP and the DCE-MRI endpoints are log-normally distributed but RAMRIS synovitis score is not. Therefore geometric mean and intra-subject CoV
were calculated for VEP and the DCE-MRI endpoints, while arithmetic mean and intra-subject SD were calculated for RAMRIS synovitis score. The
intra-class correlation coefficients were respectively 0.958 for RAMRIS synovitis score and 0.777 for Ktrans . RAMRIS synovitis score is based on an
ordinal scale (0–24) so there is a restriction on how many values the synovitis score can actually take, therefore increasing the chance of a repeatable
result. Given this, a direct comparison in repeatability with Ktrans is difficult
CoV coefficient of variation,DCE-MRI dynamic contrast-enhancedMRI, IAUC60 IAUC120/mM.s initial area under the Gd-CA concentration curve over
60 s or 120 s post-arrival in tissue, IRE/ mM.s-1 initial rate (gradient) of enhancement following Gd-CA over 60 s post-arrival in tissue, Ktrans /min-1
volume transfer constant for Gd-CA between blood plasma and extravascular extracellular space,ME/mM maximum enhancement of Gd-CA concen-
tration curve during DCE-MRI series, RAMRIS RA MRI score, SD standard deviation, T1 /s longitudinal relaxation time, ve volume of extravascular
extracellular space per unit volume tissue, vp volume of blood plasma volume per unit volume tissue, VEP/ml volume of enhancing pannus
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patients (from 19 centres) provided technically valid DCE-MRI
(Fig. S6); 45 were randomised and treated; 31 (52% of target)
provided DCE-MRI and RAMRIS scores at week 6, and 19
(32% of target) at week 24 (Table 2). At week 6, Ktrans was
66% of baseline (geometric mean, N = 10) with adalimumab
(range 27–154%); 104% of baseline (N = 11) (66–240%) with
fostamatinib; and 124% of baseline (N = 10) (66–517%) with
placebo (Fig. S2).
Discussion
MRI biomarkers [13] pose different challenges to soluble bio-
markers. Biomarker quality and validity depends on operation of
an MRI device not primarily designed for quantitative work,
perhaps in a manner unfamiliar to users in trial sites.
Encouraging measures of repeatability and response to therapy
in small studies in single expert centres may not translate to real-
world multicentre trials. It is therefore necessary to evaluate [14]
these biomarkers specifically in the multicentre setting.
Previously, various MRI biomarkers have been derived from
Gd-CA-enhanced images. The rationale for selecting our pre-
ferred DCE-MRI biomarker, Ktrans, and our exploratory bio-
markers, is described in detail in the Supplementary Material.
While many previous DCE-MRI studies in RA used variants
of the heuristic parameters IRE andME, in thisworkwe followed
international standardisation projects and guidelines [15] in
employing Ktrans. Unlike the case with CT or nuclear medicine,
in DCE-MRI the signal intensity has a non-linear relationship to
Gd-CA concentration [16] which depends in a complex way on
baseline T1, B1 heterogeneity, flow artefacts, pulse sequence pa-
rameters and post-processing. Metrics dependent on the native
signal intensities necessarily incorporate these dependencies, and
while there should little effect on repeatability when patients are
imaged in the same scanner, they make values difficult to com-
pare between scanners (or even between upgrades of the same
scanner). Thus while the MR signal intensity-based heuristic
biomarkers can exhibit good repeatability single-centre [17] they
were inappropriate for the present study.
For our preferred DCE-MRI biomarker, Ktrans, the
multicentre intra-subject repeatability coefficient of variation
(CoV) of 30%was similar to a previous single-centre RA report
[18] but worse than typically seen in oncology studies [6] where
repeatability CoV of 15% is more typical. This likely reflects
our choice to average over all joints including those with little
(or no) synovitis. At week 6 Ktrans clearly distinguished the
inferior effect of fostamatinib from adalimumab on synovial
inflammation, but failed to distinguish fostamatinib from pla-
cebo. This is interpreted as an early effect of adalimumab, but
not fostamatinib, on synovial capillary blood flow and/or cap-
illary endothelial permeability. Themain OSKIRA-4 [10] study
(N = 279) concluded fostamatinib at the two higher dose regi-
mens was more efficacious than placebo at week 6 but less than
adalimumab at week 24 in terms of RA signs and symptoms. In
this substudy, RAMRIS findings are consistent with the main
study at week 6, but the number of substudy patients at week 24
Table 2 Change from baseline of the synovial MRI biomarkers in response to intervention
Biomarker Fostamatinib (N = 11) vs.
placebo (N = 10) at 6 weeks
Fostamatinib (N = 11) vs.
adalimumab (N = 10) at 6 weeks
Fostamatinib (N = 6) vs.
adalimumab (N = 5) at 24 weeks
Treatment ratio* (tr) or
difference (td) (90% CI)
Two-sided
p-value
Treatment ratio* (tr) or
difference (td) (90% CI)
Two-sided
p-value
Treatment ratio* (tr) or
difference (td) (90% CI)
Two-sided
p-value
Ktrans tr = 0.95 (0.68–1.33) 0.794 tr = 1.92 (1.36–2.72) 0.003 tr = 1.59 (0.95–2.68) 0.137
IRE tr = 0.86 (0.62–1.18) 0.417 tr = 1.55 (1.12–2.15) 0.031 tr = 1.60 (1.06–2.42) 0.064
IAUC60 tr = 0.91 (0.66–1.24) 0.603 tr = 1.67 (1.21–2.30) 0.012 tr = 1.57 (0.97–2.54) 0.120
IAUC120 tr = 0.88 (0.65–1.19) 0.478 tr = 1.67 (1.22–2.28) 0.010 tr = 1.60 (0.98–2.61) 0.116
VEP tr = 0.85 (0.66–1.08) 0.130 tr = 0.77 (0.60–1.00) 0.053 tr = 1.23 (0.62–2.11) 0.508
ME tr = 0.95 (0.70–1.28) 0.756 tr = 1.64 (1.20–2.25) 0.012 tr = 1.57 (1.05–2.36) 0.070
ve n/a n/a n/a n/a n/a n/a
vp tr = 0.90 (0.60–1.29) 0.610 tr = 1.75 (1.21–2.54) 0.016 tr = 1.75 (1.21–2.54) 0.065
RAMRIS
synovitis score
td = -2.00 (-3.25–-0.75) 0.023 td = -1.50 (-2.50–0.00) 0.175 td = 2.00 (-0.50–5.00) 0.230
DAS-28 CRP td = 0.65 (-0.11–1.41) 0.155 td = -0.13 (-0.89–0.64) 0.780 td = -1.48 (-3.43–0.47) 0.200
Based on the response at 6 weeks in the adalimumab group, the standardised response mean for Ktrans was -0.64
DAS-28 CRP Disease Activity Score 28 based on C-reactive protein
*tr is used for VEP and the DCE-MRI endpoints as they are log-normally distributed but td for the RAMRIS synovitis score and DAS-28 CRPwhich are
not:
tr <1 or td < 0 indicate an effect in favour of fostamatinib
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was too small to draw firm conclusions. Heuristic biomarkers
IAUC120, IAUC60, IRE and ME exhibited similar repeatability to
Ktrans, and similarly distinguished fostamatinib from adalimumab.
We derived IRE and ME in absolute not arbitrary (machine-
dependent) units, which probably reduced scanner-related varia-
tion from what would be expected from signal intensity-based
heuristics. vp is challenging to measure, as blood plasma consti-
tutes only a small volume fraction of the synovitis (here around
1.5%) but it did distinguish fostamatinib from adalimumab despite
worse repeatability than the other biomarkers.
Given this variability inKtrans, a future parallel group DCE-
MRI study of 20 patients per arm would give 80% power to
detect a treatment ratio of 1.67 at a two-sided significance
level of 10%.
Due to early study termination, comparisons between
groups should be interpreted with caution. All biomarkers
were exploratory without correction for multiple comparisons.
The study was not designed to compare adalimumab with
placebo, nor to compare DCE-MRI with RAMRIS, nor to test
whether early MRI changes forecast clinical outcome.
However, our findings from this truncated study do demon-
strate that DCE-MRI biomarkers are feasible and sensitive in a
large multicentre trial setting.
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